Background: Currently, a combination of intranasal corticosteroid (INCS) plus oral H-1 antihistamine (OAH) or intranasal H1 antihistamine (INAH) therapy is frequently used in the treatment of allergic rhinitis (AR). The superiority of the 2 combined treatments needs to be further examined. Objective: To identify the better of the 2 therapeutic strategies for treating AR. Methods: A literature review was performed on MEDLINE, Cochrane Library, and EMBASE databases. Following the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analyses, metaanalyses of the total nasal symptom scores and individual nasal symptom scores were pooled based on studies that compared concomitant H-1 antihistamines plus INCS with INCS alone in the treatment of AR. The pooled results were expressed as weighted mean differences between the treatments. For each selected study, we calculated the relative clinical impact based on the total nasal symptom scores as follows: 100 x (Score(Monotherapy) x Score(Combined) therapy) / Score(Monotherapy). Results: A total of 13 publications met our selection criteria, with 5066 patients. The pooled results revealed no significant weighted mean difference on the total nasal symptom scores between concomitant OAH plus INCS and INCS alone. As for the individual symptoms, the most common symptom that revealed remission was rhinorrhea, which was after OAH in combination with INCS. The combination therapy of INAH and INCS was superior to INCS alone. In an indirect comparison, the weighted mean relative clinical impact of INAH plus INCS was significantly higher than that of OAH plus INCS. Conclusion: Intranasal H-1 antihistamines have an add-on effect on intranasal corticosteroids, and the combination of intranasal H-1 antihistamines plus intranasal corticosteroid is superior to that of oral H-1 antihistamines plus intranasal corticosteroid in improving nasal symptoms for patients with AR. (C) 2020 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
基金：
National Key R&D Program
of China (2016YFC0905200), the Program for the Changjiang Scholars and Innovative
Research Team (IRT13082), the National Natural Science Foundation of China
(81630023 and 81970852), the Beijing Bai-Qian-Wan Talent Project (2019A32), and
the Public Welfare Development and Reform Pilot Project (2019-10).
第一作者机构：[1]Capital Med Univ, Minist Educ, Dept Otorhinolaryngol Head & Neck Surg, Beijing Tongren Hosp,Key Lab Otolaryngol Head & N, Beijing, Peoples R China
通讯作者：
通讯机构：[1]Capital Med Univ, Minist Educ, Dept Otorhinolaryngol Head & Neck Surg, Beijing Tongren Hosp,Key Lab Otolaryngol Head & N, Beijing, Peoples R China[2]Capital Med Univ, Dept Allergy, Beijing Tongren Hosp, Beijing, Peoples R China[3]Beijing Inst Otolaryngol, Beijing Key Lab Nasal Dis, Beijing, Peoples R China[*1]Beijing Institute of Otorhinolaryngology, No 17, Hougou Hutong, Dongcheng District, Beijing 100005, People’s Republic of China
推荐引用方式(GB/T 7714)：
Du Kun,Qing Hui,Zheng Ming,et al.Intranasal antihistamine is superior to oral H1 antihistamine as an add-on therapy to intranasal corticosteroid for treating allergic rhinitis[J].ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY.2020,125(5):589-+.doi:10.1016/j.anai.2020.06.038.
APA：
Du, Kun,Qing, Hui,Zheng, Ming,Wang, Xiangdong&Zhang, Luo.(2020).Intranasal antihistamine is superior to oral H1 antihistamine as an add-on therapy to intranasal corticosteroid for treating allergic rhinitis.ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY,125,(5)
MLA：
Du, Kun,et al."Intranasal antihistamine is superior to oral H1 antihistamine as an add-on therapy to intranasal corticosteroid for treating allergic rhinitis".ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY 125..5(2020):589-+
